Extended Data Fig. 4: Avoiding the expression of OSKM in liver and intestine diminishes adverse phenotypes and premature death associated with in vivo reprogramming.
From: In vivo reprogramming leads to premature death linked to hepatic and intestinal failure
a, Sox2 mRNA levels in in the liver, small intestine, and kidney of 4F-Flox (OSKM whole body), 4F Non-Liver, and 4F Non-Intestine mice, after 4 days of induction of in vivo reprogramming. b, Superficial body temperature upon continuous administration of doxycycline in whole body (4F-Flox), 4F Non-liver, and 4F Non-intestine mice. Data show mean ± SEM. Statistical significance was assessed by (a-b) one-way ANOVA followed by Tukey’s post hoc test.
